{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:20:02Z","timestamp":1775060402777,"version":"3.50.1"},"reference-count":42,"publisher":"e-Century Publishing Corporation","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/ldch9386","type":"journal-article","created":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T23:56:06Z","timestamp":1751241366000},"page":"4213-4224","source":"Crossref","is-referenced-by-count":1,"title":["Gut microbiota dysbiosis in alcoholic fatty liver disease: distinct microbial communities and biochemical alterations"],"prefix":"10.62347","volume":"17","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Zhuge A, Li S, Lou P, Wu W, Wang K, Yuan Y, Xia J, Li B and Li L. Longitudinal 16S rRNA sequencing reveals relationships among alterations of gut microbiota and nonalcoholic fatty liver disease progression in mice. Microbiol Spectr 2022; 10: e0004722.","DOI":"10.1128\/spectrum.00047-22"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1086078","DOI":"10.3389\/fimmu.2023.1086078","article-title":"Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy","volume":"14","author":"Zhu","year":"2023","unstructured":"Zhu LR, Li SS, Zheng WQ, Ni WJ, Cai M and Liu HP. Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy. Front Immunol 2023; 14: 1086078.","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12967-024-04996-0","article-title":"Exploring the interplay of gut microbiota, inflammation, and LDL-cholesterol: a multiomics Mendelian randomization analysis of their causal relationship in acute pancreatitis and non-alcoholic fatty liver disease","volume":"22","author":"Yan","year":"2024","unstructured":"Yan C, Bao J and Jin J. Exploring the interplay of gut microbiota, inflammation, and LDL-cholesterol: a multiomics Mendelian randomization analysis of their causal relationship in acute pancreatitis and non-alcoholic fatty liver disease. J Transl Med 2024; 22: 179.","journal-title":"J Transl Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"759306","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial","volume":"12","author":"Xue","year":"2022","unstructured":"Xue L, Deng Z, Luo W, He X and Chen Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial. Front Cell Infect Microbiol 2022; 12: 759306.","journal-title":"Front Cell Infect Microbiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"286","DOI":"10.24920\/004220","article-title":"Influence of gut microbiota and its metabolites on progression of metabolic associated fatty liver disease","volume":"38","author":"Wang","year":"2023","unstructured":"Wang YY, Lin HL, Wang KL, Que GX, Cao T, Zhu LM, Yang X and Yang XF. Influence of gut microbiota and its metabolites on progression of metabolic associated fatty liver disease. Chin Med Sci J 2023; 38: 286-296.","journal-title":"Chin Med Sci J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2021","unstructured":"Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D and Dalamaga M. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives. Biomolecules 2021; 12: 56.","journal-title":"Biomolecules"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","unstructured":"Tilg H, Adolph TE and Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab 2022; 34: 1700-1718.","journal-title":"Cell Metab"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity","volume":"3","author":"Tilg","year":"2021","unstructured":"Tilg H, Adolph TE, Dudek M and Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021; 3: 1596-1607.","journal-title":"Nat Metab"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.3390\/ijms21165820","article-title":"Gut-pancreas-liver axis as a target for treatment of NAFLD\/NASH","volume":"21","author":"Svegliati-Baroni G","year":"2020","unstructured":"Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP and Gastaldelli A. Gut-pancreas-liver axis as a target for treatment of NAFLD\/NASH. Int J Mol Sci 2020; 21: 5820.","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Su X, Chen S, Liu J, Feng Y, Han E, Hao X, Liao M, Cai J, Zhang S, Niu J, He S, Huang S, Lo K and Zeng F. Composition of gut microbiota and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Obes Rev 2024; 25: e13646.","DOI":"10.1111\/obr.13646"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.3748\/wjg.v27.i37.6161","article-title":"Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases","volume":"27","author":"SP","year":"2021","unstructured":"Sharma SP, Suk KT and Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27: 6161-6179.","journal-title":"World J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1927633","article-title":"Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis","volume":"13","author":"Rao","year":"2021","unstructured":"Rao Y, Kuang Z, Li C, Guo S, Xu Y, Zhao D, Hu Y, Song B, Jiang Z, Ge Z, Liu X, Li C, Chen S, Ye J, Huang Z and Lu Y. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes 2021; 13: 1-19.","journal-title":"Gut Microbes"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"116848","DOI":"10.1016\/j.jep.2023.116848","article-title":"Zanthoxylum bungeanum amides ameliorates nonalcoholic fatty liver via regulating gut microbiota and activating AMPK\/Nrf2 signaling","volume":"318","author":"Peng","year":"2024","unstructured":"Peng W, He CX, Li RL, Qian D, Wang LY, Chen WW, Zhang Q and Wu CJ. Zanthoxylum bungeanum amides ameliorates nonalcoholic fatty liver via regulating gut microbiota and activating AMPK\/Nrf2 signaling. J Ethnopharmacol 2024; 318: 116848.","journal-title":"J Ethnopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.3390\/cells10102634","article-title":"Gut microbiota-related cellular and molecular mechanisms in the progression of nonalcoholic fatty liver disease","volume":"10","author":"Park","year":"2021","unstructured":"Park E, Jeong JJ, Won SM, Sharma SP, Gebru YA, Ganesan R, Gupta H, Suk KT and Kim DJ. Gut microbiota-related cellular and molecular mechanisms in the progression of nonalcoholic fatty liver disease. Cells 2021; 10: 2634.","journal-title":"Cells"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Ni Y, Qian L, Siliceo SL, Long X, Nychas E, Liu Y, Ismaiah MJ, Leung H, Zhang L, Gao Q, Wu Q, Zhang Y, Jia X, Liu S, Yuan R, Zhou L, Wang X, Li Q, Zhao Y, El-Nezami H, Xu A, Xu G, Li H, Panagiotou G and Jia W. Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. Cell Metab 2023; 35: 1530-1547, e8.","DOI":"10.1016\/j.cmet.2023.08.002"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/ajg.2017.469","article-title":"ACG clinical guideline: alcoholic liver disease","volume":"113","author":"Singal","year":"2018","unstructured":"Singal AK, Bataller R, Ahn J, Kamath PS and Shah VH. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol 2018; 113: 175-194.","journal-title":"Am J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association D and American Psychiatric Association D. Diagnostic and statistical manual of mental disorders: DSM-5. American psychiatric association Washington, DC, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2307568","DOI":"10.1080\/19490976.2024.2307568","article-title":"Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation","volume":"16","author":"Min","year":"2024","unstructured":"Min BH, Devi S, Kwon GH, Gupta H, Jeong JJ, Sharma SP, Won SM, Oh KK, Yoon SJ, Park HJ, Eom JA, Jeong MK, Hyun JY, Stalin N, Park TS, Choi J, Lee DY, Han SH, Kim DJ and Suk KT. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation. Gut Microbes 2024; 16: 2307568.","journal-title":"Gut Microbes"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"109199","DOI":"10.1016\/j.cbi.2020.109199","article-title":"High fat diet-triggered non-alcoholic fatty liver disease: a review of proposed mechanisms","volume":"330","author":"Lian","year":"2020","unstructured":"Lian CY, Zhai ZZ, Li ZF and Wang L. High fat diet-triggered non-alcoholic fatty liver disease: a review of proposed mechanisms. Chem Biol Interact 2020; 330: 109199.","journal-title":"Chem Biol Interact"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1111\/bph.15768","article-title":"Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota","volume":"179","author":"Li","year":"2022","unstructured":"Li Y, Zhao D, Qian M, Liu J, Pan C, Zhang X, Duan X, Zhang Y, Jia W and Wang L. Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. Br J Pharmacol 2022; 179: 2054-2077.","journal-title":"Br J Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.dld.2023.07.014","article-title":"Association between the gut microbiota and nonalcoholic fatty liver disease: a two-sample Mendelian randomization study","volume":"55","author":"Li","year":"2023","unstructured":"Li Y, Liang X, Lyu Y, Wang K, Han L, Wang Y, Sun J and Chi C. Association between the gut microbiota and nonalcoholic fatty liver disease: a two-sample Mendelian randomization study. Dig Liver Dis 2023; 55: 1464-1471.","journal-title":"Dig Liver Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12944-021-01440-w","article-title":"Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","unstructured":"Li F, Ye J, Shao C and Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and meta-analysis. Lipids Health Dis 2021; 20: 22.","journal-title":"Lipids Health Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.chom.2020.07.007","article-title":"Microbiota and fatty liver disease-the known, the unknown, and the future","volume":"28","author":"Lang","year":"2020","unstructured":"Lang S and Schnabl B. Microbiota and fatty liver disease-the known, the unknown, and the future. Cell Host Microbe 2020; 28: 233-244.","journal-title":"Cell Host Microbe"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13046-020-01782-w","article-title":"Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARα to activate the NF-κB signaling pathway, thereby reducing liver injury via inducing gut microbiota disturbance","volume":"40","author":"Kong","year":"2021","unstructured":"Kong L, Chen J, Ji X, Qin Q, Yang H, Liu D, Li D and Sun M. Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARα to activate the NF-κB signaling pathway, thereby reducing liver injury via inducing gut microbiota disturbance. J Exp Clin Cancer Res 2021; 40: 18.","journal-title":"J Exp Clin Cancer Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s11154-023-09843-z","article-title":"Non-alcoholic fatty liver disease and gut microbial dysbiosis - underlying mechanisms and gut microbiota mediated treatment strategies","volume":"24","author":"Jayachandran","year":"2023","unstructured":"Jayachandran M and Qu S. Non-alcoholic fatty liver disease and gut microbial dysbiosis - underlying mechanisms and gut microbiota mediated treatment strategies. Rev Endocr Metab Disord 2023; 24: 1189-1204.","journal-title":"Rev Endocr Metab Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2223339","DOI":"10.1080\/19490976.2023.2223339","article-title":"Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis","volume":"15","author":"G&#xF3","year":"2023","unstructured":"Gómez-Pérez AM, Ruiz-Limón P, Salas-Salvadó J, Vioque J, Corella D, Fitó M, Vidal J, Atzeni A, Torres-Collado L, Álvarez-Sala A, Martínez MÁ, Goday A, Benaiges D, García-Gavilán J, Bernal López MR, Moreno-Indias I and Tinahones FJ. Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis. Gut Microbes 2023; 15: 2223339.","journal-title":"Gut Microbes"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12664-020-01027-w","article-title":"Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: an emerging paradigm","volume":"39","author":"UC","year":"2020","unstructured":"Ghoshal UC, Goel A and Quigley EMM. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: an emerging paradigm. Indian J Gastroenterol 2020; 39: 9-21.","journal-title":"Indian J Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"8307","DOI":"10.3390\/ijms23158307","article-title":"Gut microbiota-a future therapeutic target for people with non-alcoholic fatty liver disease: a systematic review","volume":"23","author":"Forlano","year":"2022","unstructured":"Forlano R, Sivakumar M, Mullish BH and Manousou P. Gut microbiota-a future therapeutic target for people with non-alcoholic fatty liver disease: a systematic review. Int J Mol Sci 2022; 23: 8307.","journal-title":"Int J Mol Sci"},{"key":"ref28","unstructured":"Fernández-Musoles R, García Tejedor A and Laparra JM. Immunonutritional contribution of gut microbiota to fatty liver disease. Nutr Hosp 2020; 37: 193-206."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2390164","DOI":"10.1080\/19490976.2024.2390164","article-title":"Time-restricted feeding ameliorates non-alcoholic fatty liver disease through modulating hepatic nicotinamide metabolism via gut microbiota remodeling","volume":"16","author":"Feng","year":"2024","unstructured":"Feng R, Yang W, Feng W, Huang X, Cen M, Peng G, Wu W, Wang Z, Jing Y, Long T, Liu Y, Li Z, Chang G and Huang K. Time-restricted feeding ameliorates non-alcoholic fatty liver disease through modulating hepatic nicotinamide metabolism via gut microbiota remodeling. Gut Microbes 2024; 16: 2390164.","journal-title":"Gut Microbes"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"997018","DOI":"10.3389\/fcimb.2022.997018","article-title":"Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications","volume":"12","author":"Fang","year":"2022","unstructured":"Fang J, Yu CH, Li XJ, Yao JM, Fang ZY, Yoon SH and Yu WY. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol 2022; 12: 997018.","journal-title":"Front Cell Infect Microbiol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10096-019-03746-1","article-title":"Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies","volume":"39","author":"Ebrahimzadeh Leylabadlo","year":"2020","unstructured":"Ebrahimzadeh Leylabadlo H, Ghotaslou R, Samadi Kafil H, Feizabadi MM, Moaddab SY, Farajnia S, Sheykhsaran E, Sanaie S, Shanehbandi D and Bannazadeh Baghi H. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis 2020; 39: 613-627.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/nu14010103","article-title":"Metabolic-associated fatty liver disease (MAFLD), diabetes, and cardiovascular disease: associations with fructose metabolism and gut microbiota","volume":"14","author":"Dro&#x17C","year":"2021","unstructured":"Drożdż K, Nabrdalik K, Hajzler W, Kwiendacz H, Gumprecht J and Lip GYH. Metabolic-associated fatty liver disease (MAFLD), diabetes, and cardiovascular disease: associations with fructose metabolism and gut microbiota. Nutrients 2021; 14: 103.","journal-title":"Nutrients"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","article-title":"Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review","volume":"19","author":"Di Vincenzo","year":"2024","unstructured":"Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR and Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med 2024; 19: 275-293.","journal-title":"Intern Emerg Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.3390\/ijms21155214","article-title":"Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications","volume":"21","author":"Chen","year":"2020","unstructured":"Chen J and Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int J Mol Sci 2020; 21: 5214.","journal-title":"Int J Mol Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","unstructured":"Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, Ibrahim R, Chu F, Stephens C, Jebeili H, Fragomeli V, Koay YC, Jackson M, O’Sullivan J, Weltman M, McCaughan G, El-Omar E and Zekry A. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 2021; 12: 187.","journal-title":"Nat Commun"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Bauer KC, Littlejohn PT, Ayala V, Creus-Cuadros A and Finlay BB. Nonalcoholic fatty liver disease and the gut-liver axis: exploring an undernutrition perspective. Gastroenterology 2022; 162: 1858-1875, e2.","DOI":"10.1053\/j.gastro.2022.01.058"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ecl.2023.01.004","article-title":"Metabolic-associated fatty liver disease and the gut microbiota","volume":"52","author":"TM","year":"2023","unstructured":"Barber TM, Hanson P and Weickert MO. Metabolic-associated fatty liver disease and the gut microbiota. Endocrinol Metab Clin North Am 2023; 52: 485-496.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clnesp.2021.05.012","article-title":"Contribution of gut microbiota to nonalcoholic fatty liver disease: pathways of mechanisms","volume":"44","author":"Bakhshimoghaddam","year":"2021","unstructured":"Bakhshimoghaddam F and Alizadeh M. Contribution of gut microbiota to nonalcoholic fatty liver disease: pathways of mechanisms. Clin Nutr ESPEN 2021; 44: 61-68.","journal-title":"Clin Nutr ESPEN"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M and Clément K. Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity? Gastroenterology 2020; 158: 1881-1898.","DOI":"10.1053\/j.gastro.2020.01.049"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky J","year":"2020","unstructured":"Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M and Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020; 17: 279-297.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Alisi A, McCaughan G and Grønbæk H. Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact. Hepatol Int 2024; 18 Suppl 2: 861-872.","DOI":"10.1007\/s12072-024-10674-6"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/6\/ajtr0163822.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:24Z","timestamp":1766023044000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/6\/ajtr0163822.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/ldch9386","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}